View ValuationSpineway 향후 성장Future 기준 점검 1/6Spineway 의 수익은 연간 5.4% 감소할 것으로 예상되는 반면, 연간 수익은 6.3% 로 증가할 것으로 예상됩니다. EPS는 연간 4.1% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-5.4%이익 성장률-4.12%EPS 성장률Medical Equipment 이익 성장13.3%매출 성장률6.3%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트20 Mar 2026최근 향후 성장 업데이트Price Target Changed • Mar 22Price target increased by 22% to €0.33Up from €0.27, the current price target is provided by 1 analyst. New target price is 110% above last closing price of €0.16. Stock is up 58% over the past year.Breakeven Date Change • Apr 09Forecast to breakeven in 2023The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule.Price Target Changed • Jan 20Price target decreased to €290Down from €400, the current price target is provided by 1 analyst. New target price is 15,576% above last closing price of €1.85. Stock is down 94% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €4.76 last year.Price Target Changed • Jul 26Price target increased to €0.01Up from €0.0084, the current price target is provided by 1 analyst. New target price is 9,900% above last closing price of €0.0001. Stock is down 93% over the past year. The company posted a net loss per share of €0.00012 last year.분석 기사 • Mar 22Spineway Société Anonyme's (EPA:ALSPW) Shift From Loss To ProfitWe feel now is a pretty good time to analyse Spineway Société Anonyme's ( EPA:ALSPW ) business as it appears the...Price Target Changed • Jan 27Price target raised to €0.01Up from €0.0084, the current price target is provided by 1 analyst. The new target price is 809% above the current share price of €0.0011. As of last close, the stock is down 82% over the past year.모든 업데이트 보기Recent updates공시 • May 01Spineway SA to Report First Half, 2026 Results on Jul 30, 2026Spineway SA announced that they will report first half, 2026 results on Jul 30, 2026New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.4% per year for the foreseeable future. Market cap is less than US$10m (€3.13m market cap, or US$3.61m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.5m net loss in 2 years). Share price has been volatile over the past 3 months (9.4% average weekly change).Price Target Changed • Mar 22Price target increased by 22% to €0.33Up from €0.27, the current price target is provided by 1 analyst. New target price is 110% above last closing price of €0.16. Stock is up 58% over the past year.공시 • Mar 09Spineway SA, Annual General Meeting, Apr 02, 2026Spineway SA, Annual General Meeting, Apr 02, 2026. Location: 7 allee du moulin berger, batiment 7, ecully FranceReported Earnings • Feb 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €12.4m (down 2.4% from FY 2024). Net loss: €2.24m (loss narrowed 42% from FY 2024).New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.64m market cap, or US$4.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.4% average weekly change).분석 기사 • Jan 23Spineway SA's (EPA:ALSPW) Subdued P/S Might Signal An OpportunityYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Spineway SA ( EPA:ALSPW ) is definitely a stock worth...공시 • Jan 14Spineway SA to Report Fiscal Year 2025 Results on Feb 17, 2026Spineway SA announced that they will report fiscal year 2025 results on Feb 17, 2026분석 기사 • Oct 09A Piece Of The Puzzle Missing From Spineway SA's (EPA:ALSPW) 57% Share Price ClimbThe Spineway SA ( EPA:ALSPW ) share price has done very well over the last month, posting an excellent gain of 57...분석 기사 • Oct 08Is Spineway (EPA:ALSPW) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Aug 04First half 2025 earnings releasedFirst half 2025 results: Revenue: €5.57m (down 16% from 1H 2024). Net loss: €1.42m (loss narrowed 58% from 1H 2024).분석 기사 • Jul 29Investors Aren't Entirely Convinced By Spineway SA's (EPA:ALSPW) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.2x Spineway SA ( EPA:ALSPW ) is a stock worth checking...New Risk • Jun 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 22x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (over 22x increase in shares outstanding). Market cap is less than US$10m (€2.86m market cap, or US$3.31m). Minor Risk Currently unprofitable and not forecast to become profitable next year (€300k net loss next year).공시 • May 02Spineway SA, Annual General Meeting, Jun 04, 2025Spineway SA, Annual General Meeting, Jun 04, 2025. Location: 7 allee du moulin berger, batiment 7, ecully FranceReported Earnings • Mar 25Full year 2024 earnings releasedFull year 2024 results: Revenue: €12.0m (up 5.2% from FY 2023). Net loss: €3.86m (loss narrowed 41% from FY 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Medical Equipment industry in France.공시 • Jan 23Spineway SA to Report Fiscal Year 2024 Results on Mar 24, 2025Spineway SA announced that they will report fiscal year 2024 results on Mar 24, 2025New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€132.6k market cap, or US$143.1k). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€300k net loss in 2 years).공시 • Jul 25Spineway SA to Report First Half, 2024 Results on Sep 24, 2024Spineway SA announced that they will report first half, 2024 results on Sep 24, 2024분석 기사 • Mar 19Not Many Are Piling Into Spineway SA (EPA:ALSPW) Stock Yet As It Plummets 32%Unfortunately for some shareholders, the Spineway SA ( EPA:ALSPW ) share price has dived 32% in the last thirty days...공시 • Feb 09Spineway SA, Annual General Meeting, Mar 25, 2024Spineway SA, Annual General Meeting, Mar 25, 2024.Reported Earnings • Feb 09Full year 2023 earnings releasedFull year 2023 results: Revenue: €10.5m (up 23% from FY 2022). Net loss: €6.51m (loss widened 108% from FY 2022).분석 기사 • Jan 31Market Might Still Lack Some Conviction On Spineway SA (EPA:ALSPW) Even After 162% Share Price BoostSpineway SA ( EPA:ALSPW ) shareholders are no doubt pleased to see that the share price has bounced 162% in the last...공시 • Jan 26Spineway SA to Report Q4, 2023 Results on Feb 07, 2024Spineway SA announced that they will report Q4, 2023 results on Feb 07, 2024공시 • Nov 08Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive OfficerThe Spineway Group announced the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group. After earning a degree as a biomedical engineer (UT Compiègne) and an Executive MBA at HEC in Paris, Sandrine Carle worked for over 20 years in the orthopedic surgery sector, and more specifically in the spinal surgery sector at Medtronic (Europe), Kyphon (USA) and Vexim (France). She held marketing and management positions in France and the USA before being appointed CEO of Spine Innovations in 2020. Ms. Carle led the creation of this entity following a spin-off in 2020 and the development of this activity between 2020 and 2022. She led the recruitment and management of around fifteen employees, set up the functional and operational organization of the team and also obtained the company’s certification from the notified body, G-MED (France). Working alongside Stéphane Le Roux, CEO of Spineway, Sandrine Carle is responsible for conducting the Group’s overall roadmap, in particular the business development plan aimed at returning to operating breakeven, as well as all R&D projects (short, medium and long term).공시 • Oct 20Spineway Group Obtains 510(K) Clearance from the US Food and Drug Administration for its VEOS Spinal Fixation SystemSpineway Group announced the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System. This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant achievement for the Group and reinforces its strategic approach to develop its business in the US market. This recognition also demonstrates the Group's commitment to provide innovative solutions to surgeons and to put the well-being of patients first. This innovative medical device is presented at the North American Spine Society (NASS) Congress in Los Angeles until 21 October 2023. The VEOS Spinal Fixations System is a complete platform that offers an innovative and versatile solution tailored to surgeons' needs. The VEOS platform is easy to use, fully modular and optimizes operational excellence in operating room. This new offering enables surgeons to perform open, minimally invasive and percutaneous surgery (MIS) for the treatment of a wide range of spinal pathologies, from degenerative spine to complex surgery and deformities.Reported Earnings • Sep 21First half 2023 earnings releasedFirst half 2023 results: Revenue: €5.43m (up 51% from 1H 2022). Net loss: €1.89m (loss widened 136% from 1H 2022).New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€619.2k market cap, or US$672.6k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jul 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€987.0k market cap, or US$1.09m).Breakeven Date Change • Apr 09Forecast to breakeven in 2023The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule.Reported Earnings • Feb 14Full year 2022 earnings releasedFull year 2022 results: Revenue: €7.43m (up 48% from FY 2021). Net loss: €3.14m (loss widened 98% from FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Medical Equipment industry in France.공시 • Feb 02Spineway SA to Report First Half, 2023 Results on Sep 19, 2023Spineway SA announced that they will report first half, 2023 results on Sep 19, 2023공시 • Jan 25Spineway SA to Report Fiscal Year 2022 Results on Feb 09, 2023Spineway SA announced that they will report fiscal year 2022 results After-Market on Feb 09, 2023Price Target Changed • Jan 20Price target decreased to €290Down from €400, the current price target is provided by 1 analyst. New target price is 15,576% above last closing price of €1.85. Stock is down 94% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €4.76 last year.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 09First half 2022 earnings releasedFirst half 2022 results: Revenue: €3.11m (up 27% from 1H 2021). Net loss: €803.0k (loss widened 30% from 1H 2021).Price Target Changed • Jul 26Price target increased to €0.01Up from €0.0084, the current price target is provided by 1 analyst. New target price is 9,900% above last closing price of €0.0001. Stock is down 93% over the past year. The company posted a net loss per share of €0.00012 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.분석 기사 • Apr 12Is Spineway (EPA:ALSPW) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Feb 04Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: €0 (up from €0.005 loss in FY 2020). Revenue: €5.04m (up 12% from FY 2020). Net loss: €1.58m (loss narrowed 89% from FY 2020). Revenue missed analyst estimates by 39%. Earnings per share (EPS) exceeded analyst estimates.분석 기사 • Dec 27Spineway Société Anonyme (EPA:ALSPW) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • May 14Is Spineway Société Anonyme (EPA:ALSPW) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Mar 22Spineway Société Anonyme's (EPA:ALSPW) Shift From Loss To ProfitWe feel now is a pretty good time to analyse Spineway Société Anonyme's ( EPA:ALSPW ) business as it appears the...Reported Earnings • Jan 28Full year 2020 earnings released: €0.005 loss per share (vs €0.064 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €4.51m (down 19% from FY 2019). Net loss: €14.1m (loss widened 390% from FY 2019). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 94% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Jan 28Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 48%. Earnings per share (EPS) exceeded analyst estimates by 29%. Over the next year, revenue is forecast to grow 55%, compared to a 1,649% growth forecast for the Medical Equipment industry in France.분석 기사 • Jan 28Spineway Société Anonyme (EPA:ALSPW) Has Debt But No Earnings; Should You Worry?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Price Target Changed • Jan 27Price target raised to €0.01Up from €0.0084, the current price target is provided by 1 analyst. The new target price is 809% above the current share price of €0.0011. As of last close, the stock is down 82% over the past year.Reported Earnings • Oct 30First half earnings releasedOver the last 12 months the company has reported total losses of €13.3m, with losses widening by 249% from the prior year. Total revenue was €5.06m over the last 12 months, down 17% from the prior year.이익 및 매출 성장 예측ENXTPA:ALSPW - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202715-2-5-1112/31/202613-2-5-1112/31/202513-200N/A9/30/202512-200N/A6/30/202512-211N/A3/31/202512-3-1-1N/A12/31/202413-4-3-3N/A9/30/202412-6-6-5N/A6/30/202412-8-8-7N/A3/31/202412-7-7-6N/A12/31/202311-7-7-6N/A9/30/202311-5-11-4N/A6/30/202311-4-15-3N/A3/31/202310-4-14-2N/A12/31/20229-3-14-2N/A9/30/20227-2-8-2N/A6/30/20226-2-3-2N/A3/31/20226-2-3-2N/A12/31/20215-2-3-2N/A9/30/20215-2-3-1N/A6/30/20215-3-2-1N/A3/31/20215-8-2-1N/A12/31/20205-14-10N/A9/30/20205-14-30N/A6/30/20205-13-40N/A3/31/20205-8-5-1N/A12/31/20196-3-6-1N/A9/30/20196-3N/A-2N/A6/30/20196-4N/A-3N/A3/31/20196-4N/A-3N/A12/31/20187-4N/A-3N/A9/30/20187-4N/A-3N/A6/30/20187-4N/A-2N/A3/31/20188-2N/A-1N/A12/31/201710-1N/A-1N/A9/30/20179-1N/A-1N/A6/30/20179-1N/A-1N/A3/31/20177-2N/A-1N/A12/31/20165-3N/A0N/A9/30/20165-2N/AN/AN/A6/30/20166-2N/A0N/A3/31/20166-2N/A0N/A12/31/20156-2N/A0N/A9/30/20156-2N/AN/AN/A6/30/20155-2N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ALSPW 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: ALSPW 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: ALSPW 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: ALSPW 의 수익(연간 6.3%)이 French 시장(연간 5.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ALSPW 의 수익(연간 6.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ALSPW의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 11:49종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Spineway SA는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mohamed KaabouniPortzamparc BNP Paribas
Price Target Changed • Mar 22Price target increased by 22% to €0.33Up from €0.27, the current price target is provided by 1 analyst. New target price is 110% above last closing price of €0.16. Stock is up 58% over the past year.
Breakeven Date Change • Apr 09Forecast to breakeven in 2023The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule.
Price Target Changed • Jan 20Price target decreased to €290Down from €400, the current price target is provided by 1 analyst. New target price is 15,576% above last closing price of €1.85. Stock is down 94% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €4.76 last year.
Price Target Changed • Jul 26Price target increased to €0.01Up from €0.0084, the current price target is provided by 1 analyst. New target price is 9,900% above last closing price of €0.0001. Stock is down 93% over the past year. The company posted a net loss per share of €0.00012 last year.
분석 기사 • Mar 22Spineway Société Anonyme's (EPA:ALSPW) Shift From Loss To ProfitWe feel now is a pretty good time to analyse Spineway Société Anonyme's ( EPA:ALSPW ) business as it appears the...
Price Target Changed • Jan 27Price target raised to €0.01Up from €0.0084, the current price target is provided by 1 analyst. The new target price is 809% above the current share price of €0.0011. As of last close, the stock is down 82% over the past year.
공시 • May 01Spineway SA to Report First Half, 2026 Results on Jul 30, 2026Spineway SA announced that they will report first half, 2026 results on Jul 30, 2026
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 5.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.4% per year for the foreseeable future. Market cap is less than US$10m (€3.13m market cap, or US$3.61m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.5m net loss in 2 years). Share price has been volatile over the past 3 months (9.4% average weekly change).
Price Target Changed • Mar 22Price target increased by 22% to €0.33Up from €0.27, the current price target is provided by 1 analyst. New target price is 110% above last closing price of €0.16. Stock is up 58% over the past year.
공시 • Mar 09Spineway SA, Annual General Meeting, Apr 02, 2026Spineway SA, Annual General Meeting, Apr 02, 2026. Location: 7 allee du moulin berger, batiment 7, ecully France
Reported Earnings • Feb 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €12.4m (down 2.4% from FY 2024). Net loss: €2.24m (loss narrowed 42% from FY 2024).
New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.64m market cap, or US$4.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.4% average weekly change).
분석 기사 • Jan 23Spineway SA's (EPA:ALSPW) Subdued P/S Might Signal An OpportunityYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Spineway SA ( EPA:ALSPW ) is definitely a stock worth...
공시 • Jan 14Spineway SA to Report Fiscal Year 2025 Results on Feb 17, 2026Spineway SA announced that they will report fiscal year 2025 results on Feb 17, 2026
분석 기사 • Oct 09A Piece Of The Puzzle Missing From Spineway SA's (EPA:ALSPW) 57% Share Price ClimbThe Spineway SA ( EPA:ALSPW ) share price has done very well over the last month, posting an excellent gain of 57...
분석 기사 • Oct 08Is Spineway (EPA:ALSPW) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Aug 04First half 2025 earnings releasedFirst half 2025 results: Revenue: €5.57m (down 16% from 1H 2024). Net loss: €1.42m (loss narrowed 58% from 1H 2024).
분석 기사 • Jul 29Investors Aren't Entirely Convinced By Spineway SA's (EPA:ALSPW) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.2x Spineway SA ( EPA:ALSPW ) is a stock worth checking...
New Risk • Jun 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 22x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (over 22x increase in shares outstanding). Market cap is less than US$10m (€2.86m market cap, or US$3.31m). Minor Risk Currently unprofitable and not forecast to become profitable next year (€300k net loss next year).
공시 • May 02Spineway SA, Annual General Meeting, Jun 04, 2025Spineway SA, Annual General Meeting, Jun 04, 2025. Location: 7 allee du moulin berger, batiment 7, ecully France
Reported Earnings • Mar 25Full year 2024 earnings releasedFull year 2024 results: Revenue: €12.0m (up 5.2% from FY 2023). Net loss: €3.86m (loss narrowed 41% from FY 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Medical Equipment industry in France.
공시 • Jan 23Spineway SA to Report Fiscal Year 2024 Results on Mar 24, 2025Spineway SA announced that they will report fiscal year 2024 results on Mar 24, 2025
New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€132.6k market cap, or US$143.1k). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€300k net loss in 2 years).
공시 • Jul 25Spineway SA to Report First Half, 2024 Results on Sep 24, 2024Spineway SA announced that they will report first half, 2024 results on Sep 24, 2024
분석 기사 • Mar 19Not Many Are Piling Into Spineway SA (EPA:ALSPW) Stock Yet As It Plummets 32%Unfortunately for some shareholders, the Spineway SA ( EPA:ALSPW ) share price has dived 32% in the last thirty days...
공시 • Feb 09Spineway SA, Annual General Meeting, Mar 25, 2024Spineway SA, Annual General Meeting, Mar 25, 2024.
Reported Earnings • Feb 09Full year 2023 earnings releasedFull year 2023 results: Revenue: €10.5m (up 23% from FY 2022). Net loss: €6.51m (loss widened 108% from FY 2022).
분석 기사 • Jan 31Market Might Still Lack Some Conviction On Spineway SA (EPA:ALSPW) Even After 162% Share Price BoostSpineway SA ( EPA:ALSPW ) shareholders are no doubt pleased to see that the share price has bounced 162% in the last...
공시 • Jan 26Spineway SA to Report Q4, 2023 Results on Feb 07, 2024Spineway SA announced that they will report Q4, 2023 results on Feb 07, 2024
공시 • Nov 08Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive OfficerThe Spineway Group announced the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group. After earning a degree as a biomedical engineer (UT Compiègne) and an Executive MBA at HEC in Paris, Sandrine Carle worked for over 20 years in the orthopedic surgery sector, and more specifically in the spinal surgery sector at Medtronic (Europe), Kyphon (USA) and Vexim (France). She held marketing and management positions in France and the USA before being appointed CEO of Spine Innovations in 2020. Ms. Carle led the creation of this entity following a spin-off in 2020 and the development of this activity between 2020 and 2022. She led the recruitment and management of around fifteen employees, set up the functional and operational organization of the team and also obtained the company’s certification from the notified body, G-MED (France). Working alongside Stéphane Le Roux, CEO of Spineway, Sandrine Carle is responsible for conducting the Group’s overall roadmap, in particular the business development plan aimed at returning to operating breakeven, as well as all R&D projects (short, medium and long term).
공시 • Oct 20Spineway Group Obtains 510(K) Clearance from the US Food and Drug Administration for its VEOS Spinal Fixation SystemSpineway Group announced the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System. This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant achievement for the Group and reinforces its strategic approach to develop its business in the US market. This recognition also demonstrates the Group's commitment to provide innovative solutions to surgeons and to put the well-being of patients first. This innovative medical device is presented at the North American Spine Society (NASS) Congress in Los Angeles until 21 October 2023. The VEOS Spinal Fixations System is a complete platform that offers an innovative and versatile solution tailored to surgeons' needs. The VEOS platform is easy to use, fully modular and optimizes operational excellence in operating room. This new offering enables surgeons to perform open, minimally invasive and percutaneous surgery (MIS) for the treatment of a wide range of spinal pathologies, from degenerative spine to complex surgery and deformities.
Reported Earnings • Sep 21First half 2023 earnings releasedFirst half 2023 results: Revenue: €5.43m (up 51% from 1H 2022). Net loss: €1.89m (loss widened 136% from 1H 2022).
New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€619.2k market cap, or US$672.6k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jul 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€987.0k market cap, or US$1.09m).
Breakeven Date Change • Apr 09Forecast to breakeven in 2023The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule.
Reported Earnings • Feb 14Full year 2022 earnings releasedFull year 2022 results: Revenue: €7.43m (up 48% from FY 2021). Net loss: €3.14m (loss widened 98% from FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Medical Equipment industry in France.
공시 • Feb 02Spineway SA to Report First Half, 2023 Results on Sep 19, 2023Spineway SA announced that they will report first half, 2023 results on Sep 19, 2023
공시 • Jan 25Spineway SA to Report Fiscal Year 2022 Results on Feb 09, 2023Spineway SA announced that they will report fiscal year 2022 results After-Market on Feb 09, 2023
Price Target Changed • Jan 20Price target decreased to €290Down from €400, the current price target is provided by 1 analyst. New target price is 15,576% above last closing price of €1.85. Stock is down 94% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €4.76 last year.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 09First half 2022 earnings releasedFirst half 2022 results: Revenue: €3.11m (up 27% from 1H 2021). Net loss: €803.0k (loss widened 30% from 1H 2021).
Price Target Changed • Jul 26Price target increased to €0.01Up from €0.0084, the current price target is provided by 1 analyst. New target price is 9,900% above last closing price of €0.0001. Stock is down 93% over the past year. The company posted a net loss per share of €0.00012 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
분석 기사 • Apr 12Is Spineway (EPA:ALSPW) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Feb 04Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: €0 (up from €0.005 loss in FY 2020). Revenue: €5.04m (up 12% from FY 2020). Net loss: €1.58m (loss narrowed 89% from FY 2020). Revenue missed analyst estimates by 39%. Earnings per share (EPS) exceeded analyst estimates.
분석 기사 • Dec 27Spineway Société Anonyme (EPA:ALSPW) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • May 14Is Spineway Société Anonyme (EPA:ALSPW) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Mar 22Spineway Société Anonyme's (EPA:ALSPW) Shift From Loss To ProfitWe feel now is a pretty good time to analyse Spineway Société Anonyme's ( EPA:ALSPW ) business as it appears the...
Reported Earnings • Jan 28Full year 2020 earnings released: €0.005 loss per share (vs €0.064 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €4.51m (down 19% from FY 2019). Net loss: €14.1m (loss widened 390% from FY 2019). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 94% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Jan 28Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 48%. Earnings per share (EPS) exceeded analyst estimates by 29%. Over the next year, revenue is forecast to grow 55%, compared to a 1,649% growth forecast for the Medical Equipment industry in France.
분석 기사 • Jan 28Spineway Société Anonyme (EPA:ALSPW) Has Debt But No Earnings; Should You Worry?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Price Target Changed • Jan 27Price target raised to €0.01Up from €0.0084, the current price target is provided by 1 analyst. The new target price is 809% above the current share price of €0.0011. As of last close, the stock is down 82% over the past year.
Reported Earnings • Oct 30First half earnings releasedOver the last 12 months the company has reported total losses of €13.3m, with losses widening by 249% from the prior year. Total revenue was €5.06m over the last 12 months, down 17% from the prior year.